Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CMLSusan Branford, Timothy P. Hughes, Chani Field et al.|Blood|2013Cited by 177
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsDavid T Yeung, Timothy P. Hughes, Michael Osborn et al.|Blood|2014Cited by 102